Paratek Pharmaceuticals, Inc. hosted an Investor Day on 10/16/17 in New York City
It’s the eve of a new year. So this seems like a great moment to look at the outlook for biotech stocks in 2016. The sector has staged a big comeback following the summertime slaughter that ravaged the industry, with the iShares Nasdaq Biotechnology ETF (IBB) climbing 19% since late September. But at Leerink, the firm’s favorite biotech names are yanked from the universe of small- and mid-cap names, a list that includes Paratek Pharmaceuticals.
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to report top-line data in mid-2016. The company had previously estimated that this trial would report top-line data in the second half of 2016. The revised estimate reflects to